Short Interest in Check-Cap Ltd (NASDAQ:MBAI) Declines By 63.5%

Check-Cap Ltd (NASDAQ:MBAI) was the recipient of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 65,685 shares, a decline of 63.5% from the May 14th total of 180,004 shares. Based on an average daily volume of 73,927 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Check-Cap has a consensus rating of “Sell”.

Check-Cap Stock Up 1.5%

Shares of Check-Cap stock traded up $0.02 on Friday, hitting $1.39. 31,129 shares of the company’s stock traded hands, compared to its average volume of 70,794. The firm has a 50-day moving average price of $1.64. The company has a market cap of $10.13 million, a PE ratio of -0.50 and a beta of 0.59. Check-Cap has a one year low of $0.59 and a one year high of $3.92.

Check-Cap Company Profile

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.